Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study

被引：0

作者：

Kuemmel, Sherko ^{[1
,2
]}

Schmid, Peter ^{[3
]}

Harbeck, Nadia ^{[4
]}

Takahashi, Masato ^{[5
]}

Untch, Michael ^{[6
]}

Boileau, Jean-Francois ^{[7
]}

Cortes, Javier ^{[8
,9
]}

McArthur, Heather ^{[10
]}

Dent, Rebecca ^{[11
]}

O'Shaughnessy, Joyce ^{[12
]}

Pusztai, Lajos ^{[13
]}

Foukakis, Theodoros ^{[14
,15
]}

Park, Yeon Hee ^{[16
]}

Hui, Rina ^{[17
,18
]}

Cardoso, Fatima ^{[19
]}

Denkert, Carsten ^{[20
,21
]}

Zhu, Yalin ^{[22
]}

Pan, Wilbur ^{[22
]}

Karantza, Vassiliki ^{[22
]}

Fasching, Peter A. ^{[23
]}

机构：

[1] Kliniken Essen Mitte, Breast Unit, Essen, Germany

[2] Charite Univ Med Berlin, Dept Gynecol Breast Ctr, Berlin, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] LMU Univ Hosp, Breast Ctr, Munich, Germany

[5] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[6] Helios Klinikum Berlin Buch, Breast Canc Ctr, Berlin, Germany

[7] McGill Univ, Jewish Gen Hosp Segal Canc Ctr, Montreal, PQ, Canada

[8] Quiron Grp, Int Breast Canc Ctr, Pangaea Oncol, Barcelona, Spain

[9] Univ Europea Madrid, Madrid, Spain

[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA

[11] Duke Natl Univ Singapore Med Sch, Natl Canc Ctr Singapore, Singapore, Singapore

[12] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA

[13] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[14] Karolinska Inst, Solna, Sweden

[15] Karolinska Univ Hosp, Breast Canc Ctr, Karolinska Comprehens Canc Ctr, Solna, Sweden

[16] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[17] Westmead Hosp, Westmead Breast Canc Inst, Sydney, NSW, Australia

[18] Univ Sydney, Sydney, NSW, Australia

[19] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[20] Philipps Univ Marburg, Inst Pathol, Marburg, Germany

[21] Univ Hosp Marburg, Marburg, Germany

[22] Merck & Co Inc, Rahway, NJ USA

[23] Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany

来源：

ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1462344

引用

页码：S295 / S296

页数：2

共 50 条

[1] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Kuemmel, S.
Schmid, P.
Harbeck, N.
Takahashi, M.
Untch, M.
Boileau, J. -F.
Cortes, J.
McArthur, H.
Dent, R.
O'Shaughnessy, J.
Pusztai, L.
Foukakis, T.
Park, Y. H.
Hui, R.
Cardoso, F.
Denkert, C.
Zhu, Y.
Pan, W.
Karantza, V.
Fasching, P.
BREAST, 2023, 68 : S63 - S64
[2] HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
Dent, R. A.
Cortes, J.
Pusztai, L.
McArthur, H. L.
Kuemmel, S.
Bergh, J.
Denkert, C.
Park, Y. H.
Hui, R.
Harbeck, N.
Takahashi, M.
Untch, M.
Fasching, P. A.
Cardoso, F.
Haiderali, A.
Jia, L.
Nguyen, A. M.
Pan, W.
O'Shaughnessy, J.
Schmid, P.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S600 - S601
[3] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
McArthur, Heather
Cortes, Javier
Dent, Rebecca
O'Shaughnessy, Joyce
Pusztai, Lajos
Kuemmel, Sherko
Foukakis, Theodoros
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Untch, Michael
Fasching, Peter A.
Cardoso, Fatima
Denkert, Carsten
Zhu, Yalin
Ding, Yu
Pan, Wilbur
Schmid, Peter
CANCER RESEARCH, 2023, 83 (05)
[4] KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer
McArthur, Heather
Cortes, Javier
Dent, Rebecca
Pusztai, Lajos
Kuemmel, Sherko
Bergh, Jonas
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Untch, Michael
Fasching, Peter A.
Cardoso, Fatima
Andersen, Jay
Patt, Debra
Danso, Michael
Ferreira, Marta
Mouret-Reynier, Marie-Ange
Im, Seock-Ah
Ahn, Jin-Hee
Gion, Maria
Baron-Hay, Sally
Boileau, Jean-Francois
Zhu, Yalin
Pan, Wilbur
Tryfonidis, Konstantinos
Karantza, Vassiliki
O'Shaughnessy, Joyce
Schmid, Peter
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 338 - 338
[5] KEYNOTE-522 study of neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
Schmid, Peter
Cortes, Javier
Dent, Rebecca
Pusztai, Lajos
McArthur, Heather
Kummel, Sherko
Bergh, Jonas
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Untch, Michael
Fasching, Peter A.
Cardoso, Fatima
Andersen, Jay
Patt, Debra
Danso, Michael
Ferreira, Marta
Mouret-Reynier, Marie-Ange
Im, Seock-Ah
Ahn, Jin-Hee
Gion, Maria
Baron-Hay, Sally
Boileau, Jean-Francois
Zhu, Yalin
Pan, Wilbur
Tryfonidis, Konstantinos
Karantza, Vassiliki
O'Shaughnessy, Joyce
CANCER RESEARCH, 2022, 82 (04)
[6] KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
Schmid, P.
Cortes, J.
Dent, R.
Pusztai, L.
McArthur, H.
Kummel, S.
Bergh, J.
Denkert, C.
Park, Y. H.
Hui, R.
Harbeck, N.
Takahashi, M.
Untch, M.
Fasching, P. A.
Cardoso, F.
Ding, Y.
Tryfonidis, K.
Aktan, G.
Karantza, V.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2021, 32 (09) : 1198 - 1200
[7] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for highrisk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
Schmid, P.
Cortes, J.
Dent, R. A.
McArthur, H. L.
Pusztai, L.
Kummel, S.
Denkert, C.
Park, Y. H.
Hui, R.
Harbeck, N.
Takahashi, M.
Im, S-A.
Untch, M.
Fasching, P. A.
Cardoso, F.
Zhao, J.
Zhou, X.
Tryfonidis, K. E.
Aktan, G.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2024, 35 : 1204 - 1205
[8] Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Schmid, P.
Cortes, J.
Dent, R. A.
Pusztai, L.
McArthur, H. L.
Kummel, S.
Denkert, C.
Park, Y. H.
Hui, R.
Harbeck, N.
Takahashi, M.
Foukakis, T.
Reynier, M. A. Mouret
Ferreira, M. I. R.
Im, S. A.
Cardoso, F.
Ding, Y.
Pan, W.
Tryfonidis, K. E.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1257 - S1257
[9] Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
Cortes, Javier
Dent, Rebecca
Pusztai, Lajos
McArthur, Heather
Kuemmel, Sherko
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Takahashi, Masato
Barrios, Carlos
Zhu, Yalin
Zhang, Xiaoli
Pan, Wilbur
Karantza, Vassiliki
O'Shaughnessy, Joyce
Schmid, Peter
CANCER RESEARCH, 2024, 84 (09)
[10] Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522
Schmid, Peter
Cortes, Javier
Dent, Rebecca
Pusztai, Lajos
McArthur, Heather
Kuemmel, Sherko
Bergh, Jonas
Denkert, Carsten
Park, Yeon Hee
Hui, Rina
Harbeck, Nadia
Takahashi, Masato
Untch, Michael
Fasching, Peter A.
Cardoso, Fatima
Andersen, Jay
Patt, Debra
Danso, Michael
Ferreira, Marta
Mouret-Reynier, Marie-Ange
Im, Seock-Ah
Ahn, Jin Hee
Gion, Maria
Baron-Hay, Sally
Boileau, Jean-Francois
Zhu, Yalin
Pan, Wilbur
Tryfonidis, Konstantinos
Karantza, Vassiliki
O'Shaughnessy, Joyce
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 117 - 118

← 1 2 3 4 5 →